StemCells, Inc. Announces Strategic Realignment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
StemCells (STEM) PT Cut to $3 at Maxim Group
December 23, 2015 12:18 PM ESTMaxim Group analyst Jason Kolbert lowered his price target on StemCells (NASDAQ: STEM) to $3.00 (from $5.00) but maintained a Buy rating after the company suspended the phase II AMD (Radiant) study to focus on the spinal cord injury (SCI) trial.
Stem's management announced the decision to focus on the spinal cord injury (SCI) trial. Management will suspend the company's phase II AMD (Radiant)... MoreUPDATE: StemCells (STEM) Declines After Shares Resume Trading
December 23, 2015 8:10 AM EST(Updated - December 23, 2015 8:16 AM EST)
StemCells (NASDAQ: STEM) Declines After Shares Resume Trading
... More